MetaVia (NASDAQ:MTVA) Trading Up 2.4% – Here’s What Happened

MetaVia Inc. (NASDAQ:MTVA) traded up 2.4% during mid-day trading on Wednesday . The company traded as high as $1.8499 and last traded at $1.74. Approximately 608,754 shares traded hands during trading, an increase of 708% from the average daily volume of 75,383 shares. The stock had previously closed at $1.70.

Analyst Upgrades and Downgrades

A number of equities analysts have recently issued reports on the company. Wall Street Zen upgraded MetaVia to a “sell” rating in a report on Saturday, June 20th. HC Wainwright restated a “buy” rating on shares of MetaVia in a research report on Friday, July 10th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of MetaVia in a research note on Tuesday, July 21st. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, MetaVia currently has a consensus rating of “Hold” and an average price target of $20.00.

MetaVia Stock Performance

The stock has a market cap of $8.57 million, a P/E ratio of -0.51 and a beta of 0.94. The firm has a 50-day moving average price of $1.60 and a 200-day moving average price of $1.66.

MetaVia (NASDAQ:MTVA) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.08). On average, research analysts predict that MetaVia Inc. will post -2.79 earnings per share for the current year.

Institutional Investors Weigh In On MetaVia

An institutional investor recently bought a new stake in MetaVia stock. Virtu Financial LLC bought a new position in shares of MetaVia Inc. (NASDAQ:MTVA) during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 32,755 shares of the company’s stock, valued at approximately $31,000. Virtu Financial LLC owned 0.14% of MetaVia at the end of the most recent quarter. Hedge funds and other institutional investors own 1.37% of the company’s stock.

MetaVia Company Profile

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.